ALK and non-small cell lung carcinoma: From the US healthcare payer perspective, lorlatinib is determined not to be cost-effective when compared to crizotinib for NSCLC patients with previous untreated advanced ALK+ NSCLC at a willingness-to-pay threshold of $200,000 per QALY.